Janux shares up 90% as T cell en­gager shows ear­ly signs of PSA re­sponse in prostate can­cer

Janux Ther­a­peu­tics’ share price has rock­et­ed on the back of Phase Ia dose-es­ca­la­tion da­ta for its tu­mor-ac­ti­vat­ed T cell en­gager in ad­vanced or metasta­t­ic cas­tra­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER